Johnson & Johnson: Massive study setback:
Johnson & Johnson halts development of Nipocalimab for RA after Phase 2a failure.
deraktionaer.de/artikel/pharma-biotech/johnson-johnson-massiver-studienrueckschlag-20385648.html
Story Details
| Last Updated | |
| Total Articles | 1 |
Main Topics
U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer
Similar to This
Previous
Multiple Myeloma: A Cure in Sight?: In Austria, approximately 2,500 people are affected by multiple myeloma*. For this disease, which used to be almost a death ...
diepresse.com/38640598/multiples-myelom-heilung-in-sicht
Pols & Politics: Kennealy advisor lashes out at pro-Healey poll numbers: A poll testing Gov. Maura Healey's approval ratings drew a testy response from one ...
bostonherald.com/2025/09/14/pols-politics-advisor-to-mike-kennealy-lashes-out-at-well-known-pollster-over-healeys-approval-ratings/
Next